SEC Form 4 · accession 0001203311-16-000116
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Aug 8, 2016
Accepted (ET)
Aug 10, 2016 · 7:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 8, 2016 | M | 4,042 | $10.20 | A | 560,157 | D | |
| Common StockF3,F1 | Aug 8, 2016 | S | 4,042 | $46.9183 | D | 556,115 | D | |
| Common StockF1 | Aug 8, 2016 | M | 7,618 | $4.45 | A | 563,733 | D | |
| Common StockF4,F1 | Aug 8, 2016 | S | 7,618 | $47.3311 | D | 556,115 | D | |
| Common Stock | holding | — | — | — | 27,945 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $4.45 | Aug 8, 2016 | M | 7,618 | D | — | Sep 5, 2016 | Common Stock | 7,618 | 7,611 | D |
| Non-Qualified Stock Option (right to buy)F6 | $10.20 | Aug 8, 2016 | M | 4,042 | D | — | May 25, 2017 | Common Stock | 4,042 | 35,575 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $46.77 to $47.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $47.06 to $48.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 9/06/07 and monthly thereafter until all the shares were fully vested on 9/06/10.
- F6Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.